ArticleFrontiers in toxicology2026
Comparative cytotoxicity and genotoxicity of commercial glyphosate-based herbicide formulations and co-formulants in human leukocyte and hepatocyte cell lines.
Article in Frontiers in toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Risk assessments usually test active ingredients but not full commercial formulations. We compared cytotoxic and genotoxic effects of three glyphosate-based herbicides (Roundup Mega, Glyfos, Fozat-480) and two co-formulants (ROKAmin SR22, EMPIGEN BB) in human HL60 (leukocyte) and HepG2 (hepatocyte) cells. Methods: Cells were exposed for 1 h to increasing concentrations (0.1-10,000 μM depending on formulation). Cytotoxicity was measured by propidium iodide staining; genotoxicity was assessed by the alkaline comet assay (tail DNA %, tail length, tail moment, Olive tail moment). Positive (100 μM H Results: Cytotoxicity occurred at lower concentrations in HL60 than HepG2. Roundup Mega and Glyfos produced the strongest genotoxic responses; Roundup Mega increased tail length in HL60 from 0.1 μM, while Glyfos produced consistent genotoxicity in HepG2 from 100 μM. Co-formulants alone showed limited genotoxicity, though ROKAmin SR22 induced DNA% in tail at higher concentrations. Genotoxic effects often occurred at sub-cytotoxic concentrations. Conclusion: Commercial GBH formulations can be more genotoxic than the active ingredient alone; formulation composition influences potency and target-cell sensitivity. These results support formulation-specific testing to improve human health risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.